Home > Publications Database > Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study > print

001     157803
005     20240617143833.0
024 7 _ |a pmid:33770527
|2 pmid
024 7 _ |a 10.1016/S1474-4422(21)00027-2
|2 doi
024 7 _ |a 1474-4422
|2 ISSN
024 7 _ |a 1474-4465
|2 ISSN
024 7 _ |a altmetric:102551462
|2 altmetric
024 7 _ |a 33770527
|2 pmid
037 _ _ |a DZNE-2021-01260
082 _ _ |a 610
100 1 _ |a Reetz, Kathrin
|b 0
245 _ _ |a Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study
260 _ _ |a London
|c 2021
|b Lancet Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718627839_25685
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia.Methods: EFACTS is a prospective, observational cohort study based on an ongoing and open-ended registry. Patients with genetically confirmed Friedreich's ataxia were seen annually at 11 clinical centres in seven European countries (Austria, Belgium, France, Germany, Italy, Spain, and the UK). Data from baseline to 4-year follow-up were included in the current analysis. Our primary endpoints were the Scale for the Assessment and Rating of Ataxia (SARA) and the activities of daily living (ADL). Linear mixed-effect models were used to analyse annual disease progression for the entire cohort and subgroups defined by age of onset and ambulatory abilities. Power calculations were done for potential trial designs. This study is registered with ClinicalTrials.gov, NCT02069509.Findings: Between Sept 15, 2010, and Nov 20, 2018, of 914 individuals assessed for eligibility, 602 patients were included. Of these, 552 (92%) patients contributed data with at least one follow-up visit. Annual progression rate for SARA was 0·82 points (SE 0·05) in the overall cohort, and higher in patients who were ambulatory (1·12 [0·07]) than non-ambulatory (0·50 [0·07]). ADL worsened by 0·93 (SE 0·05) points per year in the entire cohort, with similar progression rates in patients who were ambulatory (0·94 [0·07]) and non-ambulatory (0·91 [0·08]). Although both SARA and ADL showed slightly greater worsening in patients with typical onset (symptom onset at ≤24 years) than those with late onset (symptom onset ≥25 years), differences in progression slopes were not significant. For a 2-year parallel-group trial, 230 (115 per group) patients would be required to detect a 50% reduction in SARA progression at 80% power: 118 (59 per group) if only individuals who are ambulatory are included. With ADL as the primary outcome, 190 (95 per group) patients with Friedreich's ataxia would be needed, and fewer patients would be required if only individuals with early-onset are included.Interpretation: Our findings for stage-dependent progression rates have important implications for clinicians and researchers, as they provide reliable outcome measures to monitor disease progression, and enable tailored sample size calculation to guide upcoming clinical trial designs in Friedreich's ataxia.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Activities of Daily Living
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Europe
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Friedreich Ataxia: complications
|2 MeSH
650 _ 2 |a Friedreich Ataxia: pathology
|2 MeSH
650 _ 2 |a Friedreich Ataxia: physiopathology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Mobility Limitation
|2 MeSH
650 _ 2 |a Registries
|2 MeSH
650 _ 2 |a Time Factors
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Dogan, Imis
|b 1
700 1 _ |a Hilgers, Ralf-Dieter
|b 2
700 1 _ |a Giunti, Paola
|b 3
700 1 _ |a Parkinson, Michael H
|b 4
700 1 _ |a Mariotti, Caterina
|b 5
700 1 _ |a Nanetti, Lorenzo
|b 6
700 1 _ |a Dürr, Alexandra
|0 P:(DE-2719)9000429
|b 7
|u dzne
700 1 _ |a Ewenczyk, Claire
|b 8
700 1 _ |a Boesch, Sylvia
|b 9
700 1 _ |a Nachbauer, Wolfgang
|b 10
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 11
|u dzne
700 1 _ |a Stendel, Claudia
|0 P:(DE-2719)2812141
|b 12
|u dzne
700 1 _ |a Rodríguez de Rivera Garrido, Francisco Javier
|b 13
700 1 _ |a Rummey, Christian
|b 14
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 15
|u dzne
700 1 _ |a Hayer, Stefanie
|0 P:(DE-2719)2813263
|b 16
|u dzne
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 17
|u dzne
700 1 _ |a Giordano, Ilaria
|0 P:(DE-2719)2811662
|b 18
|u dzne
700 1 _ |a Didszun, Claire
|b 19
700 1 _ |a Rai, Myriam
|b 20
700 1 _ |a Pandolfo, Massimo
|b 21
700 1 _ |a Schulz, Jörg B
|b 22
700 1 _ |a Labrum, Robyn
|b 23
700 1 _ |a Thomas-Black, Gilbert
|b 24
700 1 _ |a Manso, Katarina
|b 25
700 1 _ |a Solanky, Nita
|b 26
700 1 _ |a Gellera, Cinzia
|b 27
700 1 _ |a Mongelli, Alessia
|b 28
700 1 _ |a Castaldo, Anna
|b 29
700 1 _ |a Fichera, Mario
|b 30
700 1 _ |a Palau, Francesc
|b 31
700 1 _ |a O'Callaghan, Mar
|b 32
700 1 _ |a Biet, Marie
|b 33
700 1 _ |a Monin, Marie Lorraine
|b 34
700 1 _ |a Eigentler, Andreas
|b 35
700 1 _ |a Indelicato, Elisabetta
|b 36
700 1 _ |a Amprosi, Matthias
|b 37
700 1 _ |a Radelfahr, Florentine
|0 P:(DE-2719)9001446
|b 38
|u dzne
700 1 _ |a Bischoff, Almut T.
|b 39
700 1 _ |a Holtbernd, Florian
|b 40
700 1 _ |a Brcina, Nikolina
|b 41
700 1 _ |a Hohenfeld, Christian
|b 42
700 1 _ |a Koutsis, Georgios
|b 43
700 1 _ |a Breza, Marianthi
|b 44
700 1 _ |a Bertini, Enrico
|b 45
700 1 _ |a Vasco, Gessica
|b 46
773 _ _ |a 10.1016/S1474-4422(21)00027-2
|g Vol. 20, no. 5, p. 362 - 372
|0 PERI:(DE-600)2079704-7
|n 5
|p 362 - 372
|t The lancet / Neurology
|v 20
|y 2021
|x 1474-4422
856 4 _ |u https://pub.dzne.de/record/157803/files/DZNE-2021-01260_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/157803/files/DZNE-2021-01260_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:157803
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9000429
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2810704
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812141
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2810795
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-2719)2813263
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2810314
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)2811662
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 38
|6 P:(DE-2719)9001446
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-09
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET NEUROL : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a IF >= 50
|0 StatID:(DE-HGF)9950
|2 StatID
|b LANCET NEUROL : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-2719)7000003
|k U Clinical Researchers - München
|l U Clinical Researchers - München
|x 0
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 1
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 2
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 3
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger 1
|l Translational Neurodegeneration
|x 4
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Patient Studies
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)7000003
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1210001
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21